Luminex Co. (NASDAQ:LMNX) has been given a consensus recommendation of “Hold” by the nine brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $27.00.
LMNX has been the subject of a number of recent analyst reports. BidaskClub upgraded Luminex from a “hold” rating to a “buy” rating in a report on Wednesday, October 31st. Citigroup decreased their price target on Luminex from $34.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, November 6th. ValuEngine upgraded Luminex from a “buy” rating to a “strong-buy” rating in a report on Monday, October 29th. TheStreet downgraded Luminex from a “b-” rating to a “c+” rating in a report on Friday, December 14th. Finally, Zacks Investment Research downgraded Luminex from a “hold” rating to a “sell” rating in a report on Friday, January 18th.
Institutional investors and hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC grew its position in Luminex by 7,572.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 7,289 shares of the medical instruments supplier’s stock valued at $215,000 after buying an additional 7,194 shares during the last quarter. California Public Employees Retirement System grew its position in Luminex by 4.0% in the 2nd quarter. California Public Employees Retirement System now owns 93,724 shares of the medical instruments supplier’s stock valued at $2,768,000 after buying an additional 3,632 shares during the last quarter. Northern Trust Corp grew its position in Luminex by 1.3% in the 2nd quarter. Northern Trust Corp now owns 967,694 shares of the medical instruments supplier’s stock valued at $28,575,000 after buying an additional 12,587 shares during the last quarter. Bank of Montreal Can lifted its holdings in Luminex by 542.7% in the third quarter. Bank of Montreal Can now owns 8,316 shares of the medical instruments supplier’s stock valued at $252,000 after acquiring an additional 7,022 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in Luminex by 81.4% in the third quarter. Russell Investments Group Ltd. now owns 262,184 shares of the medical instruments supplier’s stock valued at $7,882,000 after acquiring an additional 117,685 shares during the period. Institutional investors own 83.70% of the company’s stock.
Luminex stock traded up $0.79 during trading hours on Tuesday, reaching $24.62. 281,735 shares of the company’s stock were exchanged, compared to its average volume of 313,383. Luminex has a twelve month low of $18.62 and a twelve month high of $35.37. The company has a market cap of $1.10 billion, a P/E ratio of 51.29, a PEG ratio of 5.62 and a beta of 0.81.
Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, February 4th. The medical instruments supplier reported $0.04 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.08). Luminex had a return on equity of 4.61% and a net margin of 5.81%. The business had revenue of $81.10 million for the quarter, compared to analyst estimates of $80.76 million. During the same quarter in the previous year, the business posted $0.20 earnings per share. The business’s revenue was up 3.7% on a year-over-year basis. Analysts forecast that Luminex will post 0.29 earnings per share for the current fiscal year.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.